tolazamide has been researched along with Diabetes Mellitus, Type 2 in 17 studies
Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.
tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insulin requirements, C-peptide levels, and serum lipids have been assessed in 12 obese, insulin-requiring (greater than 60 U/day) patients with type II diabetes mellitus, in a randomized crossover fashion with two treatment regimens: NPH alone and combined NPH and tolazamide, over a period of 3 months each, with maintenance of weight and glycemic control (HgA1, 2hpp and mean 24h glucose profile) at comparable levels." | 9.06 | Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus. ( Kitabchi, AE; Lawson-Grant, V; Radparvar, A; Soria, AG, 1987) |
| "Insulin requirements, C-peptide levels, and serum lipids have been assessed in 12 obese, insulin-requiring (greater than 60 U/day) patients with type II diabetes mellitus, in a randomized crossover fashion with two treatment regimens: NPH alone and combined NPH and tolazamide, over a period of 3 months each, with maintenance of weight and glycemic control (HgA1, 2hpp and mean 24h glucose profile) at comparable levels." | 5.06 | Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus. ( Kitabchi, AE; Lawson-Grant, V; Radparvar, A; Soria, AG, 1987) |
| "Glyburide and other sulfonylureas consistently enhance receptor binding in cells from patients with non-insulin-dependent diabetes mellitus, whereas no effects and mixed effects have been demonstrated in cells from patients with insulin-dependent diabetes mellitus and in normal cells, respectively." | 3.67 | Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects. ( Gavin, JR, 1985) |
| "In these NIDDM patients, exposure of pancreatic beta-cells to sustained levels of sulfonylureas induces a reversible state of refractoriness to acute stimulation with sufonylureas but not to another secretagogue." | 1.27 | Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. ( Karam, JH; Nolte, MS; Salamon, E; Sanz, N, 1986) |
| "We compared 24 obese Pima Indians with NIDDM to 24 Pima Indians with normal glucose tolerance to determine whether resting metabolic rate changes may be an additional factor influencing the weight shifts." | 1.27 | Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy. ( Bogardus, C; Howard, BV; Lillioja, S; Mott, D; Taskinen, MR; Zawadzki, J, 1986) |
| " A short 12-week study was conducted which incorporated a cross-over design and the results were examined by variance analysis after dosage was individualized to the patient's requirements." | 1.24 | CLINICAL STUDIES OF TOLAZAMIDE AND TOLBUTAMIDE: COMPARATIVE EFFECTIVENESS OF CONTROL OF DIABETES MELLITUS. ( ANDERSON, DO; RENNIE, CS, 1963) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (88.24) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| RENNIE, CS | 1 |
| ANDERSON, DO | 1 |
| Barnett, JH | 1 |
| Barnett, SM | 1 |
| Peter, SA | 1 |
| Schmitt, JK | 1 |
| Johns, SB | 1 |
| Pugh, JA | 1 |
| Wagner, ML | 1 |
| Sawyer, J | 1 |
| Ramirez, G | 1 |
| Tuley, M | 1 |
| Friedberg, SJ | 1 |
| Firth, R | 1 |
| Bell, P | 1 |
| Marsh, M | 1 |
| Rizza, RA | 2 |
| Reich, A | 1 |
| Abraira, C | 1 |
| Brunken, R | 1 |
| Soneru, I | 1 |
| Longnecker, MP | 1 |
| Elsenhans, VD | 1 |
| Leiman, SM | 1 |
| Owen, OE | 1 |
| Boden, G | 1 |
| Firth, RG | 1 |
| Bell, PM | 1 |
| Maloff, BL | 1 |
| Boyd, BK | 1 |
| Karam, JH | 1 |
| Sanz, N | 1 |
| Salamon, E | 1 |
| Nolte, MS | 1 |
| Kitabchi, AE | 1 |
| Soria, AG | 1 |
| Radparvar, A | 1 |
| Lawson-Grant, V | 1 |
| Davis, FB | 1 |
| Van Son, A | 1 |
| Davis, PJ | 1 |
| Edwards, L | 1 |
| Gavin, JR | 1 |
| Bogardus, C | 1 |
| Taskinen, MR | 2 |
| Zawadzki, J | 1 |
| Lillioja, S | 1 |
| Mott, D | 1 |
| Howard, BV | 2 |
| Squire, KM | 1 |
| Snyder, MM | 1 |
| Paulshock, BZ | 1 |
| Xiaoren, P | 1 |
| Harper, I | 1 |
| Foley, JE | 1 |
| Cheung, MC | 1 |
1 review available for tolazamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glic | 1992 |
5 trials available for tolazamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glic | 1992 |
Effects of tolazamide and exogenous insulin on pattern of postprandial carbohydrate metabolism in patients with non-insulin-dependent diabetes mellitus. Results of randomized crossover trial.
Topics: Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dietary Carbohydrates | 1987 |
Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mell | 1986 |
Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Erythrocytes; Glycate | 1986 |
Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dr | 1987 |
12 other studies available for tolazamide and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
CLINICAL STUDIES OF TOLAZAMIDE AND TOLBUTAMIDE: COMPARATIVE EFFECTIVENESS OF CONTROL OF DIABETES MELLITUS.
Topics: Biomedical Research; Diabetes Mellitus, Type 2; Glycosuria; Humans; Hypoglycemic Agents; Tolazamide; | 1963 |
Lichenoid drug reactions to chlorpropamide and tolazamide.
Topics: Aged; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Eruptions; Humans; Lichen Planus; Male; Tolaza | 1984 |
Remission of diabetes mellitus in a geriatric patient.
Topics: Aged; Diabetes Mellitus, Type 2; Humans; Male; Remission, Spontaneous; Tolazamide | 1984 |
Altering therapy of type II diabetes mellitus from insulin to tolazamide increases blood pressure in spite of weight loss.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Diabetes Mellitus, Type 2; Female; Hemoglobins; Huma | 1995 |
Potentiation of glucose-stimulated insulin release by tolazamide and paradoxical absence of glucose facilitation (Staub effect) in non-insulin-dependent diabetes.
Topics: Diabetes Mellitus, Type 2; Glucose; Humans; Insulin; Insulin Secretion; Lactates; Lactic Acid; Stimu | 1986 |
Physiologic and cellular insulin action in a glucose-intolerant model of type 2 (non-insulin-dependent) diabetes in rats.
Topics: Adipose Tissue; Animals; Biological Transport, Active; Blood Glucose; Diabetes Mellitus, Experimenta | 1986 |
Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM.
Topics: Aged; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Humans; Hyperglycemia; Is | 1986 |
Urinary diluting capacity in elderly diabetic subjects.
Topics: Aged; Aging; Chlorpropamide; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular F | 1986 |
Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects.
Topics: Adipose Tissue; Animals; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mel | 1985 |
Increased resting metabolic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy.
Topics: Adolescent; Adult; Blood Glucose; Calorimetry; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy | 1986 |
Blood glucose monitoring in a type II diabetic.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glycated Hemoglobin; Humans; Middl | 1985 |
Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus.
Topics: Adipose Tissue; Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Female; | 1985 |